Lea Pace
Medical · San Diego, CANPI 1710211180
Payments from drug & device makers
Across 93 payments — averaging $20.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$439
- GSK$326
- Novo Nordisk$311
- Lilly USA, LLC$174
- Biohaven Pharmaceuticals, Inc.$106
- Amarin Pharma, Inc.$85
- plus $490 from 15 others
What the payments were for
- Food & beverage$1,930100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 20 | $439 |
| GSK | 14 | $326 |
| Novo Nordisk | 15 | $311 |
| Lilly USA, LLC | 8 | $174 |
| Biohaven Pharmaceuticals, Inc. | 5 | $106 |
| Amarin Pharma, Inc. | 5 | $85 |
| Eisai Inc. | 4 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $61 |
| Amgen | 3 | $57 |
| Exact Sciences | 2 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Halozyme Inc | 2 | $34 |
| Galderma Laboratories, L.p. | 2 | $33 |
| Novartis | 1 | $25 |
| Merz North America, Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $23 |
| Solta Medical, A Division Of Bausch Health US, LLC | 1 | $22 |
| AstraZeneca | 1 | $20 |
| Dexcom, Inc. | 1 | $19 |
| Coopersurgical, Inc. | 1 | $18 |
| Seqirus USA Inc | 1 | $16 |
How this compares
$1,930 in reported general payments places this provider in the 70th percentile of 2,087 medical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 60 | $60,174 |
| EliquisApixaban | 12 | $12,301 |
| MounjaroTirzepatide | 11 | $11,462 |
| JardianceEmpagliflozin | 13 | $10,044 |
| GemtesaVibegron | 19 | $8,686 |
| SynthroidLevothyroxine Sodium | 28 | $2,963 |
| Atorvastatin Calcium | 109 | $994 |
| Telmisartan | 13 | $586 |
| Rosuvastatin Calcium | 42 | $460 |
| Olmesartan Medoxomil | 21 | $415 |
| Lisinopril | 56 | $336 |
| Levothyroxine Sodium | 27 | $268 |
| Tamsulosin Hcl | 16 | $252 |
| Losartan Potassium | 25 | $212 |
| Alendronate Sodium | 20 | $199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $311 | $60,17460 claims |
| Lilly USA, LLCMounjaro | $174 | $11,46211 claims |
| AbbVieSynthroid | $439 | $2,96328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,087 medical providers in California.
Other medical in San Diego
- Cheryl KyinnSan Diego$103K
- Touraj YariSan Diego$27K
- Aaron WillcottSan Diego$23K
- Yuchao JinSan Diego$22K
- Carter CopelandSan Diego$17K
- Cameron ChanSan Diego$16K
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- David DoriguzziLancaster$514K
- Alison GracomIrvine$467K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.